title: CC-10004 .
abstract: CC-10004, a phosphodiesterase 4 inhibitor and selective cytokine inhibitor, is under development by Celgene for the potential treatment of asthma, chronic obstructive pulmonary disease, inflammation and psoriasis. By October 2004, phase II trials in psoriasis had commenced.
authors.affiliation: Synovo GmbH, Paul Ehrlich Strasse 15, D-72076 Tubingen, Germany.
authors.forename: Moussa
authors.initials: M
authors.lastname: Khobzaoui
authors.forename: Hans-Jürgen
authors.initials: HJ
authors.lastname: Gutke
authors.forename: Michael
authors.initials: M
authors.lastname: Burnet
mesh_terms: D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors* / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D001249:Asthma / Q000188:drug therapy; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D016207:Cytokines / Q000037:antagonists & inhibitors* / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy
chemical_list: D016207:Cytokines; D010726:Phosphodiesterase Inhibitors; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4